Stereotaxis shares are trading lower. The company on Thursday announced it intends to initiate a trial to support CE Mark submission for its MAGiC catheter and said the European Notified Body has requested clinical data to support the submission.
Portfolio Pulse from Benzinga Newsdesk
Stereotaxis announced its intention to initiate a trial for CE Mark submission for its MAGiC catheter. The European Notified Body requested clinical data to support the submission, causing STXS shares to trade lower.
June 16, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stereotaxis shares are trading lower due to the announcement of a trial for CE Mark submission for its MAGiC catheter and the European Notified Body's request for clinical data.
The announcement of the trial for CE Mark submission and the request for clinical data by the European Notified Body may cause delays in the approval process, which could negatively impact Stereotaxis' revenue and growth prospects in the short term. This has led to a decline in STXS shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100